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Sllnlmal'y 
The effects of biweekly intravenous injections of Staphylococcus  Enterotoxin B  (SEB) into 
autoimmune MRL, Ipr/lpr (MRL/Ipr) mice were investigated.  Rather than causing the expansion 
of VB8 + T cells, SEB administration resulted in the reduction of VB8 +, CD4- CDS- "double- 
negative" (DN) T cells. This was shown by FACS  |  analysis as this putative pathogenic population 
was diminished in both spleen and lymph node. The symptoms of systemic lupus erythematosus 
(SLE) in MRL/Ipr, which include high titers of anti-DNA antibodies and circulating immune 
complexes and proteinuria, were reduced in SEB-treated mice in a dose-dependent manner. The 
clinical parameters of SLE in MRL/~, which include lymph node hyperplasia and necrotic vasculitis, 
were suppressed in 50-#g SEB-treated  mice. T  cells bearing V~6 T  cell receptor,  which does 
not interact with SEB, were not reduced with SEB administration. Thus, disease suppression 
was associated with a specific reduction in the number of V~8 +, DN T  cells. These results 
implicate a possible  therapeutic role of superantigen-based immunotherapy in V~/-restricted, 
T  cell-dominated clinical  syndromes. 
S 
uperantigens (SuperAgs) 1 are molecules that in associa- 
tion with class II MHC activate T cells based solely on 
the V~ chain of the TCK (1, 2). These antigens are the most 
powerful polyclonal mitogens known, stimulating a large 
proportion of both murine and human T cells. The minor 
lymphocyte stimulating (Mls) antigen, a self-SuperAg, has 
recently been reported to be encoded by a retrovirus, but the 
Mls antigen has yet to be isolated (3-7). More is known about 
the bacterial Super_Ags, particularly the Staphylococcus aureus 
enterotoxin series (SEs), whose sequence and structure have 
been documented (1). SuperAgs are known to exert powerful 
effects on the developing TCR repertoire in both CD4 § and 
CD8 + T cells (8-11). Previous data from this laboratory  (12, 
13) and others (14) have demonstrated both clonal anergy 
and deletion of peripheral T cells bearing reactive V~/8 TCK 
with in vivo administration of one of these SuperAgs, Staph- 
ylococcus Enterotoxin B  (SEB),  which  engages  V/~7 and 
8-bearing T  cells (2,  8). 
Recent work on different animal models of disease has 
demonstrated a V~ predominance of T cells involved in dis- 
ease pathogenesis. Examples of this phenomenon include ex- 
perimental allergic encephalomyelitis (EAE) in B10.PL mice 
(15) and lupus nephritis in MRL/Ipr (16), both of which show 
a V/38 restriction in T cells. Specific immunotherapies aimed 
at intervention at the level of these pathogenic T cells have 
included anti-V/~8 antibody (Ab) (17) and V~8 peptide therapy 
(18) in EAE, and anti-T cell (Thy-l.2 [19]), CD4 [20], B220 
[21]) Ab treatment in MRL/Ipr mice. These treatments have 
resulted in both the reduction in the number of "targeted" 
T cells and a corresponding improvement in the disease state. 
These findings suggested that the TCR-binding specificity 
of superantigens could be exploited for downregulation of 
T  cell,  and notably, pathogenic T  cell subpopulations ex- 
pressing TCKs of restricted heterogeneity. We have addressed 
this issue by SEB immunization of autoimmune MRL/Ipr 
mice,  in  which  CD4-CDS-  "double-negative" (DN)  T 
cells expressing V/38.2 and VBS.3 TCRs are preferentially 
represented on the peripheral, pathogenic T cells (16). We 
demonstrate that SEB treatment in MRL/Ipr mice results in 
a reduction in V~/8 +, CD4-CDS-  peripheral T cells con- 
comitant with disease suppression.  Clinical and serological 
disease activity was reduced in SEB-treated mice in a dose- 
dependent manner. 
1 Abbreviations  used in thispatx, r: Ab, antibody; DN, double negative; EAE, 
experimental  allergic  encephalomyelitis;  Mls, minor lymphocyte  stimulating; 
SA-PE, streptavidin-phycoerythrin; SE, Staphylococcus  aureus  enterotoxin 
series; SEB, Staphylococcus  Enterotoxin B; SuperAg, superantigen. 
Materials and Methods 
Animals.  MRL/Mp-Ipr/Ipr mice (4-6 wk old) were purchased 
from The Jackson Laboratory (Bar Harbor, ME). 
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Co. (St. Louis, MO). Reagents used for direct staining were biotin- 
conjugated  anti-:  VB6  (22),  V~8 (23),  CD4-PE conjugate,  and 
CDS-FITC conjugate from Becton Dickinson & Co. (Mountain 
View, CA). Secondary reagents,  streptavidin-PE  (SA-PE) and avidin- 
FITC, were also purchased from Becton Dickinson & Co. 
Treatment  of  MRL/Ipr with SEB,  Treatment of MRL / Ipr started 
at 6 wk of age before clinical  onset of disease. Animals were in- 
jected with 50, 5, and 0.5/zg of SEB in 0.2 ml PBS or PBS alone 
intravenously through  the tail vein every 2 wk. 
Fluorescence  Staining (FACS|  Spleen and axillary lymph node 
single cell suspensions from 6-too-old MRL/Ipr mice were treated 
with Tris-buffered 0.16 M  ammonium chloride to lyse the RBC. 
106 ceils were incubated with biotinylated anti-VB6  or anti-VB8 
(purified  from  the  respective  B  cell  hybridomas  by  protein 
A-Sepharose [Pharmacia Fine Chemicals, Uppsala, Sweden])  for 
30 min on ice.  The cells were then washed and incubated with 
either SA-PE (when anti-CD8-FITC was used as the second anti- 
body) or avidin-FITC (when anti-CD4-PE was used as the second 
antibody). After 30 min of incubation on ice, the cells were washed 
three times and incubated with anti-CD4-PE or anti-CD8-FITC 
(as mentioned above). Cells were washed and two-color analysis 
was performed by an Epics C  fluorocytometer (Coulter  Immu- 
nology, Hialeah, FL). 
ELISA for Anti-DNA Abs and Circulating Immune Complexes. 
Polystyrene microtiter wells coated with double-stranded DNA (ds- 
DNA) or goat Clq were the kind gift of Dr. Marilyn Baltz (Sigma 
Chemical Co.). Blood from each mouse was pooled according to 
treatment group and collected before the biweekly injections. Sera 
was diluted in 0.05%  Tween 20 in PBS at a 1:500 dilution  and 
allowed to incubate on the plates for 60 min at room temperature. 
The plates were then washed three times with PBS-Tween, and 50 
/~1 of a 1/1,000 dilution of anti-IgG and anti-IgM goat anti-mouse 
urease conjugate (Sigma Chemical Co.) was added to the plates. 
After incubation for 30 min, the plates were washed three times 
with PBS-Tween and twice with 0.15  M  NaC1.  The plates  were 
then incubated with the urease substrate solution. The urease sub- 
strate solution was made by a protocol kindly provided by Sigma 
Chemical Co. In short, 8 mg of bromcresol purple was dissolved 
in 1.48 ml of 0.01 M NaOH and then diluted to 100 mlwith water. 
100 mg of urea and 3.7 mg of EDTA were dissolved  and the pH 
was adjusted to 4.8 by the addition of 0.01  M  NaOH. Colouri- 
metric change was quantified by a Microplate Reader (MR, 600; 
Dynatech,  Chantilly,  VA) at 590 nm OD. 
Proteinuria  and Physical  Symptoms.  Urine (from at least four mice 
per group) was pooled according to treatment group. Protein con- 
centration and the presence of blood in urine was measured semi- 
quantitatively by reagent strips for urine analysis (Labstix; Ames 
Corp., Etobicoke, Ontario). Physical symptoms were visually scored 
as: 0, no symptoms; 0.5,  trace; 1-4, when visible symptoms are 
observed, with 4 being the most severe (physical symptoms include 
lymph node hyperplasia, immune complex vasculitis,  and necrosis 
of the ears).  Mortality was observed in the PBS and 0.5-#g SEB- 
treated groups at 4 mo of age.  The scores representing physical 
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Figure 1.  Circulating immune complex and anti-DNA titers as measured by ELISA. MRbl~/!pr mice were given biweekly intravenous injections 
(by tail vein) of 50, 5, and 0.5/~g of SEB in 0.2 ml PBS or PBS alone beginning at 6 wk of age. At weekly intervals, ,~200 #1 of blood was collected 
from each mouse and serum was pooled according to treatment group and stored at  -20~  (a) The results from Clq-coated plates; (b) DNA-coated 
wells. The data are representative of three separate experiments. Nonautoimmune C3H/HeJ and pre-autoimmune MRL/Ipr (4 wk of age) registered 
OD readings <0.05 at 590 nm for both assays. 50 #g SEB (e), 5 /~g SEB (O), 0.5/~g SEB (A), PBS ([2]). 
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group and then dividing by the number of animals alive in that 
group when the measurement  was taken. 
Results 
Systemic Administration of  SEB Reduces Both Immune Corn- 
flex and dsDNA-specific  Ab Titer.  Serologically, we followed 
both circulating immune complex (Fig.  1 a) and ds-DNA- 
specific antibody (Fig. 1 b) titers as measured by ELISA. The 
results show that while the PBS-injected controls manifested 
the aggressive increase in these indices correlated with dis- 
ease onset at 3 mo of age, animals treated with 50 #g SEB 
showed a pre-autoimmune level, similar to that measured in 
nonautoimmune mice. The intermediate doses of SEB (5 and 
0.5 #g) decreased both serological levels 1-1.5-fold, but did 
not have as great an effect as the 50-#g SEB treatment, which 
was associated with a fourfold difference in DNA-specific OD, 
and an eightfold difference in immune complex OD (from 
this point on, "SEB treatment" will refer to the 50-/~g-treated 
group exclusively). We have also previously observed a de- 
crease in ds-DNA-specific Ab titer using 20 #g of SEB (un- 
published observations, C.  Kim).  Thus, SEB treatment  in- 
duces a dose-dependent decrease in two serological parameters 
of SLE in MKL/Ipr mice. 
Specific Reduction of V[38  +, CD4 - CD8-  T Cells in SEB- 
treated Spleens and Lymph Nodes.  To ascertain the effects of 
SEB immunization on the peripheral V~/8 population in this 
autoimmune strain,  the proportions of V~8 + T cells in the 
splenic and lymph node CD4 + ,CD8 +, and CD4- CD8-  T 
cell populations were compared between 6-too-old controls 
and 50-#g SEB-treated mice. We were curious to determine 
if SEB could cause a decrease in peripheral VB8 + T ceils that 
were CD4-  and  CD8-.  The  results  of both  splenic  and 
lymph node analyses  show that injections of SEB does pro- 
duce a decrease in the VB8 + DN T cell fraction, from 15% 
to 2%  in spleen (Fig.  2 a)  and 22%  to 2%  in LN (Fig.  2 
b).  Interestingly,  there seemed to a compensatory increase 
in the V~6 § CD4-8-  fraction with SEB treatment,  from 
3% to 8%. However, the V~6 + DN T  cell proportion did 
not show the enormous expansion normally observed in the 
V/58 § DN T  cell fraction.  Also, SEB immunization  led to 
minimal  decreases in the proportions  of V~8 + CD4 § and 
V~8 + CD8 §  T  cells. 
The results imply that the abnormal DN T cells that are 
associated with both onset and acceleration of disease in the 
MRL/Ipr strain are more susceptible to deletion than single- 
positive cells, and/or that SEB treatment has suppressed their 
time-dependent  proliferation.  Regardless,  the results  show 
that SEB treatment  has decreased the level of these pheno- 
typically aberrant cells and results in the suppression of disease. 
Mass of  Lymphoid Organs  from SEB-treated  MRL/Ipr Mice. 
One of the phenotypic changes associated with disease onset 
is a massive lymphoid hyperplasia, which causes a profound 
increase in the size of lymphoid organs (24, 25). We there- 
fore examined the splenic and lymph node sizes of mice from 
PBS controls  and SEB-treated MRL/Ipr. 
As shown in Fig.  3, with SEB treatment,  there is a de- 
crease  in  both  the  spleen  and  the  axillary  lymph  node. 
Specifically, spleens and axiUary lymph nodes from PBS con- 
trols averaged 0.66 and 0.25 g, respectively. The SEB coun- 
terparts  weighed 0.25  and 0.04 g.  This decrease in splenic 
and  axillary lymph  node mass is due to a decrease in cell 
number in these lymphoid organs.  The other lymph nodes 
demonstrated a similar decrease in cellularity and size with 
SEB treatment  (data not  shown). 
Reduction in Proteinuria and the Physical  Symptoms of SLE. 
Disease onset in these mice occurs at 3 mo of age with visible 
lymphoid hyperplasia, increasing titers of auto-Abs, and the 
development of nephritis  with proteinuria.  50% mortality 
in the MRL/Ipr strain, due to glomerulonephritis,  occurs by 
5 mo of age.  To determine the effect of SEB treatment  on 
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Figure 2.  Flow cytometric anal- 
ysis of MKL/Ipr  spleen and lymph 
node  cells. MKL/Ipr mice  were 
treated  with  50  #g SEB  or  PBS 
alone and were killed at 6 mo of age, 
and  the  spleens  (a)  and  axillary 
lymph  nodes  (b)  were  removed. 
Single  cell suspensions  were ana- 
lyzed by two-color FACS  |  analysis 
with biotinylated anti-VB6  and -V/38 
Abs, and CD4-PE and CD8-FITC 
Abs. The results are presented as the 
mean and SD of three separate ex- 
periments. 
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Figure 3.  Mass  of lymphoid organs from MLR/IFr  mice. Spleen and 
axillary  lymph nodes  were removed  from 6-mo-old MRL/IFr  mice treated 
with 50 #g SEB or PBS and weighed. The data are presented as the mean 
mass per spleen  or axillary  lymph  node and SD of four different  experiments. 
a clinical level, we measured both renal function by assaying 
proteinuria and followed the physical symptoms of disease. 
In Table 1, it is clearly shown that SEB treatment has in- 
hibited renal degradation (0.3 g/liter at 5 mo of age), while 
the PBS controls demonstrate a gross defect in renal function 
(3.0 g/liter). The 0.5-#g SEB-treated  group shows an ap- 
parent acceleration  of renal degradation, whereas the 5-#g 
SEB-treated group reaches abnormal levels at 5 mo of age. 
In fact, by 21 wk of age, all the treatment groups, except 
50-#g SEB, show high levels of proteinuria as well as the 
presence of blood in the urine, a further indicator of glomer- 
ulonephritis. 
The visible physical symptoms that signal lupus in this 
strain include lymph node hyperplasia,  necrosis of the ears, 
and immune complex vasculitis of the skin (24, 25). Table 
2 shows that SEB treatment has been effective in suppressing 
the physical signs of disease and parallels the results of SEB 
treatment on the other parameters of SLE in the MRL/Ipr 
strain. 
Discussion 
T cell-dominated clinical syndromes in which T cells pref- 
erentially  express TCKs of restricted heterogeneity provide 
an unique opportunity to study the effects of T cell-directed 
therapies.  The use of mAbs against specific T  cell markers 
have been used in the treatment of both EAE (anti-V/38 Abs) 
and lupus in MRL/~tn"  (anti-Thy-l.2, CD4, B220). These ther- 
apies have resulted in the reduction of the "targeted" T cells 
as well as a decrease in disease activity. However, the effects 
of passive Ab therapy are generally short-lived and require 
frequent injections of large amount to be effective. 
The results presented in this report indicate a reduction 
of disease in SEB-treated MRL/Ipr  mice past 5 mo of age, 
the time when the PBS and 0.5-#g SEB groups show 50% 
mortality (data not shown; and 24, 25). However, SEB treat- 
ment does not seem to suppress the disease completely. At 
7 mo of age, some mice treated with 50/~g of SEB developed 
lymph node swelling. This, however, was not due to an ex- 
pansion of V/~8 +  or  VB6 + DN  T  cells as  measured by 
Table  1.  Proteinuria 
Treatment 
Age  50 #g SEB  5 /xg SEB  0.5  #g SEB  PBS 
Table  2.  Physical  Symptoms (Lymphoid Hyperplasia, Necrosis 
of Ear, Hair Loss) 
wk  g/liter 
12  <0.3  <0.3  1.0  1.0 
13  <0.3  <0.3  1.0  1.0-3.0 
14  <0.3  <0.3  1.0  1.0-3.0 
15  <0.3  0.3-1.0  1.0"  1.0-3.0 
16  <0.3  0.3  1.0  1.0-3.0 
17  <0.3  1.0  1.0-3.0  1.0-3.0 
18  0.3-1.0  0.3-1.0  3.0  3.0* 
19  0.3-1.0  0.3-1.0  3.0-20*  3.0 
20  0.3  1.0-3.0  3.0-20*  3.0 
21  0.3-1.0  3.0-20*  3.0-20s  3.0-20s 
Measured from 3 mo of age (by Labstix). 
* Trace, nonhemolyzed blood. 
Hemolyzed blood. 
s Large  blood. 
Treatment 
Age  50 #g SEB  5 #g SEB  0.5 #g SEB  PBS 
wk 
12  0  0  0  0 
13  0  0  0.3  0.3 
14  0  0  0.3  0.3 
15  0  0  0.35  0.4 
16  0  0  0.45  0.61 
17  0  0.1  0.85  0.67 
18  0  0.1  1.1  0.72 
19  0  0.31  0.85  0.61 
20  0  0.31  0.85  1.0 
21  0.1  0.44  0.95  1.06 
No symptoms,  0; trace, 0.5. Symptoms  scored 1-4, (4 most severe). To- 
tal score for each group is divided by total number of mice. 
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expansion of another VB DN T cell population causes dis- 
ease in SEB-treated MRL/Ipr  mice remains to be investigated. 
By 9 mo, the first indications of immune complex vasculitis 
are observed as well as mortality in this group. Thus, SEB 
treatment has a dramatic effect on delaying disease onset, but 
cannot completely abrogate the disease in this strain. 
Work from this laboratory (12, 13) has shown anergy and 
reduction of V138 +, CD4 + peripheral T  cells 21 d  after a 
single injection of 50 #g of SEB in BALB/c  mice. It is thus 
possible that reductions of disease in MRL/Ipr  mice may re- 
quire only two or three SEB injections, and this is currently 
being investigated. However, the active processes  involved 
in the development of disease in this strain may not permit 
duration of the effects of SEB injection comparable to that 
observed in BALB/c  mice. The proliferation of DN T  cells 
that is genetically programmed in MRL/Ipr  mice may over- 
come an abbreviated treatment regimen. We have observed 
that after termination of treatment at 5 mo of age, MRL/Ipr 
mice treated with 50 #g of SEB develop high levels of anti- 
DNA Abs by 10 mo of age (unpublished observations, A. 
De Hoyos and A.  Ochi). 
The data presented in this report are consistent with a cause 
and effect relationship between a decrease in DN Vt38 + T 
cells and amelioration of disease. However, a role of CD4 + 
T cells in disease pathogenesis in this strain cannot be ruled 
out. It has been previously reported that CD4 + T  cells can 
contribute to lymphoproliferation and auto-Ab production 
in MRL/Ipr  mice (20).  As we have previously shown that 
the dose of SEB used to reduce disease in MRL/Ipr  mice is 
tolerogenic for CD4 + T cells in normal mice, the possibility 
exists that these salutary effects result, in some measure, from 
anergy (but not deletion) of mature CD4 + , V138  + T  cells. 
Alternately, CD4 + T cells that are involved in disease propa- 
gation may have arisen, in part,  from the reacquisition of 
the CD4 accessory molecule by the DN T  cells in the pe- 
riphery (26-28).  Thus, it may be impossible to distinguish 
the relevance of T cell anergy vs. reduction in amelioration 
of disease in MRL/Ipr  mice. The advantage of SEB therapy, 
however, lies in the fact that SEB interacts with "reactive" 
T  cells that are CD4 + ,CD8 +, and CD4- CD8-  (29).  The 
factors that cause these reactive T  cells to undergo deletion 
or anergy when exposed to SEB remain to be determined. 
Similarly, the factors that lead to activation (30) or suppres- 
sion (12-14) of T cells consequent to in vivo SEB administra- 
tion remain to be determined. 
The application of SEB to the treatment of MRL/Ipr  mice 
provides a potential new technique in T cell--directed therapies. 
Although the data demonstrate that V~8 + CD4-CD8-  ex- 
pansion in lymphoid tissues is dramatically prevented in mice, 
the mechanisms whereby this therapy downregulates autoan- 
tibody and immune complex production are currently un- 
clear. Previous data have demonstrated that SEB injection can 
cause suppression in the humoral response in normal mice 
(31), and thus it is possible that SEB can suppress anti-DNA 
antibody-producing B cells in MRL/Ipr mice. 
The exact role of DN T  cells in disease initiation and/or 
pathogenesis remains to be elucidated. Previous reports have 
shown that these cells have undergone thymic selection and 
expression of surface CD4 and CD8 (32, 33). There are cur- 
rently two main paradigms as to the origin of these DN T 
cells  (34).  They  may  encode  TCKs  with  autoreactive 
specificities  or they may arise consequent to defective posi- 
tive selection and may not have specificity for self at all. Regard- 
less of their origins DN T cells are dearly involved in disease 
pathogenesis, and their ablatement by SEB treatment sup- 
presses  the disease. 
In an alternate approach, peptide therapy has recently been 
shown to be effective in both preventing and reversing EAE 
in Lewis rats (18). This strategy invokes a 21-amino acid pep- 
tide derived from the second complementarity determining 
region of the V/38 TCK and presumably induces an autoregula- 
tory response against V138-bearing T  cells. This treatment 
has a surprisingly rapid therapeutic effect, and the lack of 
foreign antigenic determinants as well as its extended regula- 
tory effects makes this approach very promising. So far the 
mechanism of therapeutic effects is unclear. As yet, peptide 
therapy has not been investigated in the MRL/Ipr  strain. It 
would be necessary and important to compare therapeutic 
benefits of SEB and peptide-mediated approaches. 
One potential problem associated  with SEB administra- 
tion in vivo is its enterotoxic effect. SEs are the common cause 
of food poisoning in man. However, a recent report has sug- 
gested that different portions of the SEB molecule are respon- 
sible for its T cell mitogenic and enterotoxic effects (35). Our 
observations support this contention, as no detrimental effect 
was observed in SEB-treated mice except for a transient weight 
loss of 5-10% in 50-#g-treated mice (data not shown; and 36). 
In summary, T cell-mediated pathogenesis of autoimmu- 
nity in MRL/Ipr  mice is implied by the clinical improvements 
induced by such interventions as neonatal thymectomy (37, 
38) and administration of anti-Thy-l.2 (19), CD4 (20), and 
B-220 (21) mAbs. This strain then provides a unique model 
for studying the efficacy of T cell-directed therapies at im- 
proving and/or ablating disease. We have shown that a Vfl- 
specific SuperAg that functionally inactivates and deletes pe- 
ripheral T cells markedly reduces disease activity in these au- 
toimmune mice. Whether Vl3-dominant T cells play a causa- 
tive role in disease initiation and progression or arise through 
some bystander effect remains to be elucidated. However, Vfl- 
specific therapy by SuperAgs may have potential for future 
clinical application and warrants further investigation. 
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